Zacks Small Cap Research on MSN
NSRX: NS002 phase II topline results
By John Vandermosten, CFA NYSE: NSRX Nasus (NYSE: NSRX) reported topline results from its pharmacokinetic (PK) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results